JPRN-jRCT2080224722已完成2 期
Follow-up study for the KOI2-002 study in epidermolysis bullosa patients
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with dystrophic epidermolysis bullosa who participated in the KOI2-002 study and received KOI2 treatment.
排除标准
- •Patients who are considered inappropriate for the study by the investigator or subinvestigator
研究者
相似试验
进行中（未招募）
1 期
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimensMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2017-004203-41-ESJanssen-Cilag International N.V.180
进行中（未招募）
1 期
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimensMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2017-004203-41-GBJanssen-Cilag International N.V.180
进行中（未招募）
1 期
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimensMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2017-004203-41-CZJanssen-Cilag International N.V.180
进行中（未招募）
1 期
A clinical study to evaluate the safety, effectiveness and pharmacokinetics of Daratumumab given through the subcutaneous route in combination with standard bone marrow cancer treatment regimensMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2017-004203-41-DEJanssen-Cilag International N.V.265
未知
3 期
R744 clinical traialJPRN-jRCT2080220983Chugai Pharmaceutical Co., Ltd.70